Risk factors for lower extremity lymphedema after cervical cancer treatment: a systematic review and meta-analysis
The main risk factors for the development of lower extremity lymphedema after cervical cancer treatment are controversial. Our aim was to evaluate the main risk factors of lower extremity lymphedema after cervical cancer treatment.BackgroundThe main risk factors for the development of lower extremit...
Saved in:
Published in | Translational cancer research Vol. 11; no. 6; pp. 1713 - 1721 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
AME Publishing Company
01.06.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The main risk factors for the development of lower extremity lymphedema after cervical cancer treatment are controversial. Our aim was to evaluate the main risk factors of lower extremity lymphedema after cervical cancer treatment.BackgroundThe main risk factors for the development of lower extremity lymphedema after cervical cancer treatment are controversial. Our aim was to evaluate the main risk factors of lower extremity lymphedema after cervical cancer treatment.We searched the English database PubMed, Embase, Medline, Central and the Chinese database CNKI to obtain relevant studies. Inclusion criteria: (I) the subjects were cervical cancer patients receiving treatment; (II) cohort studies or case-control studies; (III) exposure factors were not limited; (IV) the outcome was lower extremity lymphedema after treatment; (V) the odds ratio (OR) value and 95% confidence interval of exposure factors can be obtained. The chi-square test was used to test for heterogeneity. The Egger test was used to test for publication bias. OR (95% CI) was calculated using inverse variance.MethodsWe searched the English database PubMed, Embase, Medline, Central and the Chinese database CNKI to obtain relevant studies. Inclusion criteria: (I) the subjects were cervical cancer patients receiving treatment; (II) cohort studies or case-control studies; (III) exposure factors were not limited; (IV) the outcome was lower extremity lymphedema after treatment; (V) the odds ratio (OR) value and 95% confidence interval of exposure factors can be obtained. The chi-square test was used to test for heterogeneity. The Egger test was used to test for publication bias. OR (95% CI) was calculated using inverse variance.A total of 12 retrospective studies with a total of 3,401 patients were included in this literature review. The incidence of lower extremity lymphedema after cervical cancer treatment was between 12.6% and 43.1%. Meta-analysis results demonstrated that the main risk factors were: body mass index (BMI) (OR =1.37, 95% CI: 1.10-1.71, P=0.005), age (OR =1.68, 95% CI: 1.07-2.64, P=0.02), International Federation of Gynecology and Obstetrics (FIGO) stage (OR =1.50, 95% CI: 1.24-1.82, P<0.001), radiotherapy (OR =2.87, 95% CI: 1.71-4.82, P<0.001), lymph node (LN) dissection (OR =3.24, 95% CI: 1.44-7.31, P=0.005), and the number of LNs dissected (OR =2.34, 95% CI: 1.80-3.05, P<0.001). Egger's test showed that there was no publication bias among the literatures (P>0.05).ResultsA total of 12 retrospective studies with a total of 3,401 patients were included in this literature review. The incidence of lower extremity lymphedema after cervical cancer treatment was between 12.6% and 43.1%. Meta-analysis results demonstrated that the main risk factors were: body mass index (BMI) (OR =1.37, 95% CI: 1.10-1.71, P=0.005), age (OR =1.68, 95% CI: 1.07-2.64, P=0.02), International Federation of Gynecology and Obstetrics (FIGO) stage (OR =1.50, 95% CI: 1.24-1.82, P<0.001), radiotherapy (OR =2.87, 95% CI: 1.71-4.82, P<0.001), lymph node (LN) dissection (OR =3.24, 95% CI: 1.44-7.31, P=0.005), and the number of LNs dissected (OR =2.34, 95% CI: 1.80-3.05, P<0.001). Egger's test showed that there was no publication bias among the literatures (P>0.05).BMI, age, FIGO stage, radiotherapy, LN dissection and the number of LNs removed are the main risk factors for lower extremity lymphedema after cervical cancer treatment. When treating patients with cervical cancer, effective interventions should be sought to reduce the risk of lower extremity edema.ConclusionsBMI, age, FIGO stage, radiotherapy, LN dissection and the number of LNs removed are the main risk factors for lower extremity lymphedema after cervical cancer treatment. When treating patients with cervical cancer, effective interventions should be sought to reduce the risk of lower extremity edema. |
---|---|
AbstractList | The main risk factors for the development of lower extremity lymphedema after cervical cancer treatment are controversial. Our aim was to evaluate the main risk factors of lower extremity lymphedema after cervical cancer treatment.BackgroundThe main risk factors for the development of lower extremity lymphedema after cervical cancer treatment are controversial. Our aim was to evaluate the main risk factors of lower extremity lymphedema after cervical cancer treatment.We searched the English database PubMed, Embase, Medline, Central and the Chinese database CNKI to obtain relevant studies. Inclusion criteria: (I) the subjects were cervical cancer patients receiving treatment; (II) cohort studies or case-control studies; (III) exposure factors were not limited; (IV) the outcome was lower extremity lymphedema after treatment; (V) the odds ratio (OR) value and 95% confidence interval of exposure factors can be obtained. The chi-square test was used to test for heterogeneity. The Egger test was used to test for publication bias. OR (95% CI) was calculated using inverse variance.MethodsWe searched the English database PubMed, Embase, Medline, Central and the Chinese database CNKI to obtain relevant studies. Inclusion criteria: (I) the subjects were cervical cancer patients receiving treatment; (II) cohort studies or case-control studies; (III) exposure factors were not limited; (IV) the outcome was lower extremity lymphedema after treatment; (V) the odds ratio (OR) value and 95% confidence interval of exposure factors can be obtained. The chi-square test was used to test for heterogeneity. The Egger test was used to test for publication bias. OR (95% CI) was calculated using inverse variance.A total of 12 retrospective studies with a total of 3,401 patients were included in this literature review. The incidence of lower extremity lymphedema after cervical cancer treatment was between 12.6% and 43.1%. Meta-analysis results demonstrated that the main risk factors were: body mass index (BMI) (OR =1.37, 95% CI: 1.10-1.71, P=0.005), age (OR =1.68, 95% CI: 1.07-2.64, P=0.02), International Federation of Gynecology and Obstetrics (FIGO) stage (OR =1.50, 95% CI: 1.24-1.82, P<0.001), radiotherapy (OR =2.87, 95% CI: 1.71-4.82, P<0.001), lymph node (LN) dissection (OR =3.24, 95% CI: 1.44-7.31, P=0.005), and the number of LNs dissected (OR =2.34, 95% CI: 1.80-3.05, P<0.001). Egger's test showed that there was no publication bias among the literatures (P>0.05).ResultsA total of 12 retrospective studies with a total of 3,401 patients were included in this literature review. The incidence of lower extremity lymphedema after cervical cancer treatment was between 12.6% and 43.1%. Meta-analysis results demonstrated that the main risk factors were: body mass index (BMI) (OR =1.37, 95% CI: 1.10-1.71, P=0.005), age (OR =1.68, 95% CI: 1.07-2.64, P=0.02), International Federation of Gynecology and Obstetrics (FIGO) stage (OR =1.50, 95% CI: 1.24-1.82, P<0.001), radiotherapy (OR =2.87, 95% CI: 1.71-4.82, P<0.001), lymph node (LN) dissection (OR =3.24, 95% CI: 1.44-7.31, P=0.005), and the number of LNs dissected (OR =2.34, 95% CI: 1.80-3.05, P<0.001). Egger's test showed that there was no publication bias among the literatures (P>0.05).BMI, age, FIGO stage, radiotherapy, LN dissection and the number of LNs removed are the main risk factors for lower extremity lymphedema after cervical cancer treatment. When treating patients with cervical cancer, effective interventions should be sought to reduce the risk of lower extremity edema.ConclusionsBMI, age, FIGO stage, radiotherapy, LN dissection and the number of LNs removed are the main risk factors for lower extremity lymphedema after cervical cancer treatment. When treating patients with cervical cancer, effective interventions should be sought to reduce the risk of lower extremity edema. |
Author | Hu, Hongyuan Huang, Xiujin Fu, Mingru Huang, Ju Gao, Jinniao |
Author_xml | – sequence: 1 givenname: Hongyuan surname: Hu fullname: Hu, Hongyuan – sequence: 2 givenname: Mingru surname: Fu fullname: Fu, Mingru – sequence: 3 givenname: Xiujin surname: Huang fullname: Huang, Xiujin – sequence: 4 givenname: Ju surname: Huang fullname: Huang, Ju – sequence: 5 givenname: Jinniao surname: Gao fullname: Gao, Jinniao |
BookMark | eNptkUtPHDEQhK0IBAS45Qf4yCGT-LHr8XCIFCHykJAiIZC4Wb09PcGJZ7yxvQvz7zGPHIJy6pL661Kp6y3bmeJEjL2T4oOSQrcfC6ZGqUaqpXnDDpSSXWOs0DtP2jamNTf77DjnX0IIJaVdCLPH9vXSarPU-oClS59_8wGwxJT5EBMP8Y4Sp_uSaPRl5mEe17fU0wgchlJXSGnrEQJHmKrmFYQy0lROOfA851LR4pEn2nq64zD1fKQCDUwQ5uzzEdsdIGQ6fpmH7PrL-dXZt-bix9fvZ58vGtRGlgatAFpIuwJDdtW1tu8X2A44mL7vgCwIsrIDi61BS7Yf2mVnAZQSFjRaqQ_Zp2ff9WY1Uo81YYLg1smPkGYXwbt_N5O_dT_j1nWq1fVx1eDkxSDFPxvKxY0-I4UAE8VNdsp0Uixa04mKqmcUU8w50eDQl_qF-Ojsg5PCPfXlal9OKffYVz16_-rob7b_4g9v05xX |
CitedBy_id | crossref_primary_10_3389_fphar_2022_1016138 crossref_primary_10_12701_jyms_2025_42_23 crossref_primary_10_17749_2949_5873_rehabil_2024_21 crossref_primary_10_17749_2313_7347_ob_gyn_rep_2023_461 crossref_primary_10_1016_j_asjsur_2024_12_037 crossref_primary_10_1186_s12905_024_03422_3 crossref_primary_10_3390_pharmaceutics15030868 crossref_primary_10_1038_s41598_023_43503_1 crossref_primary_10_1109_LRA_2024_3375709 crossref_primary_10_17749_2313_7347_ob_gyn_rep_2023_426 crossref_primary_10_1007_s00404_024_07886_4 crossref_primary_10_1097_NCC_0000000000001425 |
ContentType | Journal Article |
Copyright | 2022 Translational Cancer Research. All rights reserved. 2022 Translational Cancer Research. All rights reserved. 2022 Translational Cancer Research. |
Copyright_xml | – notice: 2022 Translational Cancer Research. All rights reserved. – notice: 2022 Translational Cancer Research. All rights reserved. 2022 Translational Cancer Research. |
DBID | AAYXX CITATION 7X8 5PM |
DOI | 10.21037/tcr-22-1256 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2219-6803 |
EndPage | 1721 |
ExternalDocumentID | PMC9273676 10_21037_tcr_22_1256 |
GroupedDBID | 53G AAYXX ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL CITATION DIK OK1 PGMZT RPM 7X8 5PM |
ID | FETCH-LOGICAL-c361t-c80ae418ba6e8b978dd4c7fcf6dd9ae8a0e819a8c76c8e8df7598aa2208a3c813 |
ISSN | 2218-676X 2219-6803 |
IngestDate | Thu Aug 21 14:08:55 EDT 2025 Fri Jul 11 11:23:47 EDT 2025 Tue Jul 01 01:41:59 EDT 2025 Thu Apr 24 23:07:54 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 6 |
Language | English |
License | Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c361t-c80ae418ba6e8b978dd4c7fcf6dd9ae8a0e819a8c76c8e8df7598aa2208a3c813 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Contributions: (I) Conception and design: H Hu, M Fu, J Gao; (II) Administrative support: X Huang; (III) Provision of study materials or patients: H Hu, M Fu, J Gao; (IV) Collection and assembly of data: H Hu, M Fu, J Gao; (V) Data analysis and interpretation: H Hu, M Fu, J Gao; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. These authors contributed equally to this work. |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC9273676 |
PMID | 35836533 |
PQID | 2691047690 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9273676 proquest_miscellaneous_2691047690 crossref_citationtrail_10_21037_tcr_22_1256 crossref_primary_10_21037_tcr_22_1256 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-6-00 20220601 |
PublicationDateYYYYMMDD | 2022-06-01 |
PublicationDate_xml | – month: 06 year: 2022 text: 2022-6-00 |
PublicationDecade | 2020 |
PublicationTitle | Translational cancer research |
PublicationYear | 2022 |
Publisher | AME Publishing Company |
Publisher_xml | – name: AME Publishing Company |
SSID | ssj0002118406 |
Score | 2.2919562 |
SecondaryResourceType | review_article |
Snippet | The main risk factors for the development of lower extremity lymphedema after cervical cancer treatment are controversial. Our aim was to evaluate the main... |
SourceID | pubmedcentral proquest crossref |
SourceType | Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 1713 |
SubjectTerms | Original |
Title | Risk factors for lower extremity lymphedema after cervical cancer treatment: a systematic review and meta-analysis |
URI | https://www.proquest.com/docview/2691047690 https://pubmed.ncbi.nlm.nih.gov/PMC9273676 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKeOEFMQGiXCYjwdNkSJzEdvY2IaZpEjygTepbZDvuVtSmU0getl-yn8vxJbdRpMFLVLmxe_m-not7_B2EPmhJVapKSXSUGZLGkO5I8PskUVSDf5GZcs0mvn1npxfp2SJbzGZ3o6qltlGf9O3OcyX_gyqMAa72lOw_INsvCgPwGPCFKyAM1wdh_MPWhXcdc2y94Nr2PDsEe1ubjesJcQNgmdJsZGgGrp1psJogFu16qDP3h57v6zr7cuGNaSSRQb1kHM06R7futhPDkkE-6GogjHNv2-ryph2oeNL6ov3qsm6HO8Pm9WLV_lxVfwyfteM9CsC7r6XypoxCIEEYdz0Lwet0YzlhIkomtjgecW5sWGPuj6wGJ20T110OgAYNAfBihNquLdkOne17_q-vSoR8yM0vYHZBaWFnP0KPKSQgdLQPZH08pM2QGbvOhd1H86cq3AKfRy8_jXeGJGZagjuKac6foachGcHHnln7aGaq56i2rMKBVRhYhR2rcM8qPLAKO1bhjlXYUwD3rDrCEg-cwp5TGDiFJ5x6gS5Ovp5_OSWhMwfRCYsbokUkTRoLJZkRKueiLFPNl3rJyjKXRsjIQKQpheZMCyPKJc9yISWlkZCJFnHyEu1V28q8Qjg1EeeamyjTeZrBHJEozSNN46WQhqVzdNh9f4UOsvW2e8q62AXXHH3s7772ci1_ue99B0UB9tT-SSYrs21_FZTlVr2E5dEc8QlG_YJWkX36TLW6csrsOSQDwIXXD3wXb9CT4dfyFu01dWveQYzbqANHt98zzbAU |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+factors+for+lower+extremity+lymphedema+after+cervical+cancer+treatment%3A+a+systematic+review+and+meta-analysis&rft.jtitle=Translational+cancer+research&rft.au=Hu%2C+Hongyuan&rft.au=Fu%2C+Mingru&rft.au=Huang%2C+Xiujin&rft.au=Huang%2C+Ju&rft.date=2022-06-01&rft.issn=2218-676X&rft.eissn=2219-6803&rft.volume=11&rft.issue=6&rft.spage=1713&rft.epage=1721&rft_id=info:doi/10.21037%2Ftcr-22-1256&rft.externalDBID=n%2Fa&rft.externalDocID=10_21037_tcr_22_1256 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2218-676X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2218-676X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2218-676X&client=summon |